16 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 11 Not applicable, 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 9, Recruiting 1, Unknown 1 |
| Phase 1 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Product Labeling: new trials by email Literature Review of Product Labeling trials Research Report on Product Labeling
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Non-Nutrition Menu Labels on Food Selections Control (QR) Labels, Low Environmental Harm Labels, High Environmental Harm Labels - Food Selection | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 7000 | 2026-04-13 | 2026-06-12 |
| Perceptions of and Reactions to Sustainability Menu Label Designs Control (QR) Labels, Low Sustainability Labels, Unsustainable Labels - Food Choices | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 14720 | 2025-10-09 | 2026-01-07 |
| MENU Study: Online Experiment Control (QR) Labels, Low Climate Impact Labels, High Climate Impact Labels - Food Selection | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 6294 | 2025-04-01 | 2025-05-29 |
| Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT 89Zr-Patritumab deruxtecan - Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 16 | 2025-03-03 | 2026-08-10 |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy Tagraxofusp, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Stemline Therapeutics, Inc. | 85 | 2025-01-14 | 2026-08-06 |
| Climate Impact Label Design and Fast-Food Meal Selection Control (QR) Labels, Warning High Climate Impact Labels, Traffic Light Labels - Food Selection | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 6622 | 2024-12-02 | 2026-01-06 |
| Front-of-Package Nutrition Labels Positive Labels, Spectrum Labels, FDA High In Labels - Nutrition, Food Selection | Not applicable | Completed | Harvard Pilgrim Health Care | 6002 | 2024-10-31 | 2026-10-08 |
| A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702) - HIV | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 | 2025-03-26 | |
| DPA-714 and FDG PET/MRI in Depression PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG - Depression | Not applicable | Recruiting | The First Affiliated Hospital of Dalian Medical University | 70 | 2024-08-23 | 2024-11-12 |
| Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult. AdC6-HIVgp140, AdC7-HIVgp140, CH505TF gp120 - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 34 | 2021-11-25 | 2025-12-24 |
| PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy PET/CT, radioactive drug (tracer) - Cancer | Phase 1 / Phase 2 | Completed | Mayo Clinic | 6 | 2020-08-14 | 2023-09-13 |
| Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714 PET scan with tracer injection [18F] DPA-714 - Narcolepsy 1, Kleine-Levin Syndrome | Not applicable | Completed | University Hospital, Montpellier | 78 | 2019-01-15 | 2024-05-29 |
| 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC 18F-PD-L1 - NSCLC Stage IV | Not applicable | Completed | The Netherlands Cancer Institute | 80 | 2018-10-25 | 2026-02-27 |
| PET Imaging of the Immune System Using Analog Probes [18F] CFA - Malignant Melanoma | Completed | Jonsson Comprehensive Cancer Center | 4 | 2018-04-10 | 2021-10-12 | |
| The Impact of a Neutral Formulated and Designed Package Insert on Nocebo-effect. Package Insert - Orthopedic Surgery | Not applicable | Unknown | University of Witten/Herdecke | 60 | 2018-04-01 | 2018-10-09 |
| The Reduced Calorie Food and Mood Study Product Labelling and Sensory modifications - Markedly Reduced Food Intake, Satiety and Food Intake | Not applicable | Completed | Singapore Institute of Food and Biotechnology Innovation | 121 | 2017-09-09 | 2019-10-28 |
| Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA), Cardiac MRI with contrast agent, Gadovist - Coronary Artery Disease, Cardiomyopathy | Not applicable | Completed | The Methodist Hospital Research Institute | 120 | 2016-10-01 | 2026-04-20 |
| A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 TAK-935, [18F]MNI-792 (tracer) - Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | Phase 1 | Completed | Takeda | 11 | 2015-07-01 | 2026-09-15 |
| Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer Niraparib Oral Capsules (Labeled), Niraparib IV (Labeled), Niraparib Oral Capsules (Unlabeled) - Cancer | Phase 1 | Completed | Tesaro, Inc. | 12 | 2015-02-01 | 2020-01-13 |
| HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 Radiolabeled [68Ga]ABY-025 - HER2-positive Breast Cancer | Phase 1 | Terminated | Dorte Nielsen | 2 | 2011-08-01 | 2020-10-05 |
Showing 20 of 23. Sign in to see all of them.
Food Preferences (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Carcinoma (1) · Cardiomyopathies (1) · Coronary Artery Disease (1) · Depression (1) · Epilepsy (1) · Feeding Behavior (1) · HIV Infections (1) · Kleine-Levin Syndrome (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Narcolepsy 1 (1)
Johns Hopkins Bloomberg School of Public Health (4) · The Netherlands Cancer Institute (2) · Dorte Nielsen (1) · Genentech, Inc. (1) · HIV Vaccine Trials Network (1) · Harvard Pilgrim Health Care (1) · Jonsson Comprehensive Cancer Center (1) · Lantheus Biosciences Ltd. (1) · Mary Crowley Medical Research Center (1) · Mayo Clinic (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Singapore Institute of Food and Biotechnology Innovation (1) · Stemline Therapeutics, Inc. (1) · Takeda (1) · Tesaro, Inc. (1)
United States (11) · Netherlands (3) · Germany (2) · South Africa (2) · Australia (1) · China (1) · Denmark (1) · Finland (1) · France (1) · Singapore (1) · Switzerland (1)
Joop de Langen, MD (2) · Ameena Goga (1) · Anna H. Grummon, PhD (1) · Antoni Ribas, M.D. (1) · Dipan Shah, MD (1) · Egbert Smit, MD (1) · Huimin Zhang (1) · Jason P. Block, MD (1) · Jennifer Low, M.D. (1) · John Bois, MD (1) · Julia A Wolfson, PhD MPP (1) · Julia A Wolfson, PhD, MPP (1) · Julia Wolfson, PHD MPP (1) · Julia Wolfson, PhD MPP (1)
PMID 31349865, PMID 37770111, PMID 38669634, PMID 41105412, PMID 41397534, PMID 41520993, PMID 42430158
R01DK139327 (3), 2008 (1), 2017 (1), R01DK115492 (1), UM1AI068614 (1)